Roche Builds Case for MS Drug with Two-Year Efficacy Data

Roche builds case for MS drug with two-year efficacy data

Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data

Fenebrutinib Maintains Low Levels of Multiple Sclerosis Activity for 96 Weeks

Although there is no cure for MS, treatment focuses on recovery from attacks, reducing relapse, slowing disease progression, and managing multiple sclerosis symptoms.

Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor

Roche has released findings on the long-term efficacy o […] The post Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor first appeared on GeneOnline News. The post Roche Reports Near-Complete Suppression of Disability Progression in RMS Patients Over Two Years with BTK Inhibitor appeared first on GeneOnline News.

Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates

A newly presented analysis of data from the Novartis Global Safety Database and the PRIM study assessed pregnancy and infant outcomes in women with multiple sclerosis treated with ofatumumab.

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

Plus, news about Diakonos Oncology and Coherus: Roche’s longer-term data for multiple sclerosis drug: The Swiss drugmaker’s BTK inhibitor fenebrutinib achieved an annualized relapse rate of 0.06 in 93 people with ...

Roche’s Fenebrutinib Demonstrates Promising Results with Low Relapse Rates and No Disability Progression in Phase II Multiple Sclerosis Study

Roche’s Evrysdi Shows Remarkable Motor and Cognitive Outcomes in Children with SMA After Two Years of Early Treatment (IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse rate of 0.06, equivalent to …